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Introduction
Large-scale, population-based information on the survival
of patients with myeloid malignancies is scarce. This is main-
ly due to under-recognition of these diseases in past classifi-
cations. The second revision of the International
Classification of Diseases for Oncology (ICD-O-2), pub-
lished in 1990, still considered that myelodysplastic syn-
dromes (MDS) and myeloproliferative disorders were benign
and they were only recognized as malignant in the third revi-
sion (ICD-O-3).1 There were also coding difficulties associat-
ed with many of these conditions, which further discouraged
their registration by cancer registries. For many years, in fact,
acute (AML) and chronic myeloid leukemia (CML) were the
only myeloid conditions considered malignant; the latter is
caused by the t(9;22)(q34;q11) translocation resulting in the
easily recognizable Philadelphia chromosome. 
This situation was eased after correspondences were
established between the ICD-O-3 codes and the World
Health Organization (WHO) classifications of hematologic
malignancies of 20012 and 2008.3
The WHO classifications2,3 exploit many different tumor
characteristics but are based fundamentally on cell lineage,
reinforcing the distinction between lymphoid and myeloid
neoplasms. This distinction was often ignored in past epi-
demiological studies, which lumped several entities together
as ‘leukemias’.4,5 It is also important to distinguish chronic
from acute forms of these diseases, as their clinical features,
treatments and public health implications differ consider-
ably.
The restricted population-based information that is avail-
able on morphological subgroups of myeloid malignancies
mainly comes from a few specialized registries of hemato-
logic malignancies.6,7-9 The fact that these registries are few
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Population-based information on the survival of patients with myeloid malignancies is rare mainly because some
entities were not recognized as malignant until the publication of the third revision of the International
Classification of Diseases for Oncology and World Health Organization classification in 2000. In this study we
report the survival of patients with myeloid malignancies, classified by updated criteria, in Europe. We analyzed
58,800 cases incident between 1995 to 2002 in 48 population-based cancer registries from 20 European countries,
classified into HAEMACARE myeloid malignancy groupings. The period approach was used to estimate 5-year
relative survival in 2000-2002. The relative overall survival rate was 37%, but varied significantly between the
major groups: being 17% for acute myeloid leukemia, 20% for myelodysplastic/myeloproliferative neoplasms,
31% for myelodysplastic syndromes and 63% for myeloproliferative neoplasms. Survival of patients with individ-
ual disease entities ranged from 90% for those with essential thrombocythemia to 4% for those with acute
myeloid leukemia with multilineage dysplasia. Regional European variations in survival were conspicuous for
myeloproliferative neoplasms, with survival rates being lowest in Eastern Europe. This is the first paper to present
large-scale, European survival data for patients with myeloid malignancies using prognosis-based groupings of
entities defined by the third revision of the International Classification of Diseases for Oncology/World Health
Organization classifications. Poor survival in some parts of Europe, particularly for treatable diseases such as
chronic myeloid leukemia, is of concern for hematologists and public health authorities.
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and far between makes comparisons of survival of
patients with these diseases across regions and over time
problematic. These problems are compounded by the
classification difficulties mentioned above, and conse-
quent heterogeneity of disease definitions between coun-
tries, treatment centers and cancer registries. 
HAEMACARE is a European project that was set up to
improve the standardization and availability of popula-
tion-based data on hematologic malignancies.10 Under the
aegis of this project, hematologists, pathologists and epi-
demiologists from several European countries reached a
consensus on the grouping of myeloid malignancies (as
defined by ICD-O-3 morphology codes and WHO
nomenclature1-3) into larger categories based on similarity
of prognosis and, therefore, useful for epidemiological,
clinical and public health purposes. The resulting
HAEMACARE myeloid malignancy grouping system is
analogous to that proposed by the Pathology Working
Group of the International Lymphoma Epidemiology
Consortium for lymphoid neoplasms.11,12
The aim of the present study was to estimate survival
of patients with myeloid malignancies alive at some point
in 2000-2002, using data from European population-based
cancer registries, with malignancies grouped according to
the HAEMACARE system. We produced estimates of 5-
year relative survival for these disease groupings, by age
at diagnosis, and European region. 
Design and Methods
Cases and HAEMACARE groupings
We initially considered the 58,800 cases of myeloid malignan-
cy diagnosed between 1995 and 2002, archived in the EURO-
CARE-4 database,13 and contributed by 48 cancer registries in 20
European countries. 
We grouped these countries into five European regions:
Northern Europe (Iceland, Norway, Sweden), UK and Ireland
(England, Northern Ireland, Scotland, Wales, Ireland), Central
Europe (Austria, France, Germany, Switzerland, the
Netherlands), Southern Europe (Italy, Malta, Slovenia, Spain),
and Eastern Europe (Czech Republic, Poland, Slovakia). The dis-
tribution of these cases by country and cancer registry, with
selected data quality indicators, is shown in Table 1.
We next selected the cases to be analyzed based on cancer reg-
istry data quality.14 We included in the analyses only cancer reg-
istries with: (i) over 70% of cases microscopically verified; (ii)
less than 15% of cases discovered only at autopsy or on the
death certificate; and (iii) less than 30% of cases with unspeci-
fied morphology (ICD-O-3 morphology codes 9800, 9801, 9805
and 9860). This resulted in 50,328 cases from 42 cancer registries
in 17 European countries. These cases are listed in Table 2 by
ICD-O-3 code and WHO description, grouped into five major
HAEMACARE categories: acute myeloid leukemia (AML),
myeloproliferative neoplasm (MPN), myelodysplastic syndrome
(MDS), myelodysplastic/myeloproliferative neoplasm
(MDS/MPN), and myeloid malignancy of unknown type
(leukemia NOS and myeloid leukemia NOS). 
AML was divided into four HAEMACARE subgroups: AML
with recurrent cytogenetic abnormalities, AML with multilin-
eage dysplasia, AML therapy-related and AML other. The ‘AML
other’ group was subdivided according to lineage, proportion of
blast cells and presence of myelofibrosis (9931/3). MPN were
divided into CML and three morphological subgroups. 
The study protocol required that morphology be coded
according to ICD-O-3; however, cases diagnosed before the
adoption of the ICD-O-3 (about year 2000 by most registries)
were originally coded according to ICD-O-1 or ICD-O-2. These
codes were converted into ICD-O-3 using IARC and EURO-
CARE rules. However conversion was not always exact, because
new AML entities were introduced into the ICD-O-3 based on
cytogenetic and immunochemical characteristics not available in
the past. Cases not classifiable into ICD-O-3 entities were con-
verted to AML NOS, which formed a high proportion of AML in
the present study.
The ICD-O-3 classification does not differ from ICD-O-2 for
AML and myeloproliferative disorders and, therefore, the annual
number of patients diagnosed with these conditions before or
after the introduction of the ICD-O3/WHO in 2000 is fairly con-
stant. However changes introduced by ICD-O-3 for MDS and
MDS/MPN are reflected in an increase in the annual number of
cases since 2000. For MDS 50% and for MDS/MPN 43% of the
total cases included in the study (1995-2002) were diagnosed in
2000-2002.
Before 2001, refractory anemia with excess blasts in transfor-
mation (9984/3) was considered an MDS. In the WHO classifi-
cation3 the number of blast cells to define AML decreased from
30% to 20% so that some conditions previously considered
MDS were included with the AMLs. In the present study we
grouped these cases as AML with multilineage dysplasia
(9895/3) as this cytological property is characteristic of MDS.2,3
The category MDS/MPN was newly created in the WHO
2001 classification2 and confirmed in the 2008 classification.3 It
consists of chronic myelomonocytic leukemia, atypical chronic
myeloid leukemia (BCR-ABL1-negative), juvenile myelomono-
cytic leukemia, and unclassifiable myelodysplastic/myeloprolif-
erative neoplasms. 
Statistical analysis 
We investigated relative survival, a measure of the probability
of cancer survival after adjustment for competing causes of death,
and defined as the ratio of the observed survival of the group of
cancer patients of interest to the expected survival of a group of
people of the same sex, age, and year of death in the general pop-
ulation.15,16 Expected survival was estimated from cancer registry-
specific population life tables by the Hakulinen method.17
The cancer registries provided data on malignancies diagnosed
in 1995-2002 with follow up available until 2003; we used the
period method18 to give the most up-to-date estimate of 5-year
relative survival for these cases, i.e. the 5-year survival in the peri-
od 2000-2002. Using this approach a period of follow up (2000-
2002), rather than a period of diagnosis, is selected and survival is
estimated from the survival experience of patients followed up to
2000-2002, who were diagnosed in years before 2000.18 We esti-
mated the 5-year relative survival for each myeloid malignancy
grouping, by age at diagnosis and by European region. 
To compare survival by European region the data were age-
adjusted (direct method) using the same weightings as applied in
EUROCARE-4.14 The analyses were carried out using SEER STAT
software, version 6.5.1. (Information Management Services, Inc.
and Surveillance Research Program of the Division of Cancer
Control and Population Sciences, National Cancer Institute,
USA).
Results
Three of the 48 cancer registries participating in
HAEMACARE had less than 70% microscopically veri-
fied cases, three had over 15% of cases discovered at
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Table 1. Cases of myeloid malignancy diagnosed in European adults in 1995-2002, by European region, country and cancer registry, with cancer
registry data quality indicators.
European region Country/Area Cancer registry National Cases diagnosed in 1995-2002
registration (%)1
N. of cases NOS morphology2 DCO3/ Microscopically
(%) autopsy4 (%) verified4 (%) 
Northern Europe
Iceland Iceland 100 92 1 0 100
Norway Norway 100 2,181 14 3 97
Sweden Sweden 100 7,562 5 1 100
UK and Ireland
Ireland Ireland 100 2,810 14 3 96
UK, England East Anglia 5.4 2,727 3 2 76
Northern &Yorkshire 13.3 5,312 3 2 90
Oxford 5.4 1,312 6 0 100
West Midlands 10.7 4,594 6 9 74
UK, Northern Ireland Northern Ireland 100 1,259 9 1 47
UK, Scotland Scotland 100 6,473 3 1 92
UK, Wales Wales 100 2,059 8 17 57
Central Europe
Austria Austria 100 3,355 15 15 82
France Côte d’Or Hématologique 0.9 584 1 0 100
Germany Saarland 1.3 892 7 4 92
Switzerland Basel 6.1 233 2 3 99
Geneva 5.6 275 8 0 99
St. Gallen 7.2 299 7 1 100
Ticino 4.3 125 14 6 94
The Netherlands Amsterdam 17.6 996 5 0 100
Eindhoven 6.1 365 3 0 100
North Netherlands 12.9 844 5 2 100
Twente 7.2 495 6 1 100
Southern Europe
Italy Alto Adige 0.8 203 8 0 98
Biella 0.3 289 2 0 98
Ferrara 0.6 323 13 1 97
Firenze-Prato 2.0 1,386 17 1 65
Friuli Venezia Giulia 2.1 762 15 3 100
Genova 1.6 1,121 8 1 75
Modena 1.1 353 1 0 99
Napoli 0.9 177 34 1 89
Parma 0.7 425 19 0 100
Ragusa 0.5 318 7 1 98
Reggio Emilia 0.8 294 15 0 92
Romagna 1.7 774 18 5 95
Salerno 1.9 422 23 1 98
Sassari 0.8 258 5 0 100
Torino 1.6 429 6 2 93
Trento 0.8 178 20 0 100
Umbria 1.5 612 11 1 78
Veneto 3.5 897 26 3 92
Malta Malta 100 287 2 0 99
Slovenia Slovenia 100 686 7 1 100
Spain Girona 1.3 504 11 0 99
Eastern Europe
Czech Republic West Bohemia 8.3 610 14 8 85
Poland Cracow 1.9 236 36 15 80
Kielce 3.1 352 18 0 92
Warsaw 4.2 606 15 3 79
Slovakia Slovakia 100 1,454 20 12 96
Totals 58,800 8 4 88
1Proportion of national population covered by the cancer registry in 1995-1999; 2NOS: cases with poorly-specified morphology: those with ICD-O-3 morphology codes 9800, 9801, 9805,
and 9860; 3DCO: cases only discovered from death certificate; 4Percentages calculated for cases with specified morphology (i.e. excluding cases coded 9800, 9801, 9805, and 9860).
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Table 2. Distribution by sex, age at diagnosis and geographic area of patients with myeloid malignancies diagnosed in Europe in the period 1995-
2002. Frequencies are given by single ICD-O-3 morphology code and by the groupings proposed in the HAEMACARE study.
HAEMACARE ICD-O-3 code                                                 Cases     Males Distribution by age (%)             Distribution by European region (%)
grouping       and description                                                 (N)          (%)    15-49   50-69        70+     Northern  UK and     Central Southern   Eastern
                                                                                                                                                                  Europe    Ireland      Europe    Europe     Europe
Acute myeloid leukemia (AML)                                                      18,988         53          18           34               48               20              38                 13              22                 7
AML, other                                                                                           17,983          53          17           34               49               20              38                 13              22                 7
                           9840 Acute erythroid leukemia                                                                                                                                                                                                      
                           9861 AML, NOS                                                                                                                                                                                                                                  
                           9867 Acute myelomonocytic leukemia                                                                                                                                                                                         
                           9870 Acute basophilic leukemia                                                                                                                                                                                                    
                           9872 AML, minimal differentiation                                                                                                                                                                                               
                           9873 AML, without maturation                                                                                                                                                                                                       
                           9874 AML, with maturation                                                                                                                                                                                                             
                           9891 Acute monocytic leukemia                                                                                                                                                                                                    
                           9910 Acute megakaryoblastic leukemia                                                                                                                                                                                       
                           9930 Myeloid sarcoma                                                                                                                                                                                                                     
                           9931 Acute panmyelosis with myelofibrosis                                                                                                                                                                              
AML with recurrent cytogenetic abnormalities                            685             49          50           34               16               17              40                 20              19                 4
                           9866 Acute promyelocytic leukemia t(15; 17) (q22; q11-12)                                                                                                                                                  
                           9871 AML with abnormal marrow eosinophils                                                                                                                                                                           
                           9896 AML, t(8,21) (q22,q22)                                                                                                                                                                                                           
                           9897 AML, 11q23 abnormalities                                                                                                                                                                                                     
AML with multilineage dysplasia                                                       310            61           5            29               66               25              33                 24              15                 3
                           9895 AML, with multilineage dysplasia                                                                                                                                                                                        
                           9984 Refractory anemia with excess blasts in transformation (obsolete)                                                                                                                        
AML, therapy related                                                                             10             30          20           40               40                0                0                  90              10                 0
                           9920 Therapy-related AML, NOS                                                                                                                                                                                                   
                           9987 Therapy-related myelodysplastic syndrome, NOS                                                                                                                                                          
Myeloproliferative neoplasms (MPN)                                           17,927         51          16           34               50               21              49                  8               17                 6
Chronic myeloid leukemia (CML)                                                    6,794           55          24           33               42               16              31                 13              29                11
                           9863 CML, NOS                                                                                                                                                                                                                                  
                           9875 CML,  BCR/ABL1-positive                                                                                                                                                                                                       
Other myeloproliferative neoplasms                                                                                                                                                                                                                     
Subgroup 1                                                                                              66              55          36           35               29               29              15                 18              27                11
                           9740 Mastocytoma, NOS/mast cell sarcoma                                                                                                                                                                               
                           9741 Malignant mastocytosis                                                                                                                                                                                                         
                           9742 Mast cell leukemia                                                                                                                                                                                                                  
Subgroup 2                                                                                           7,579           48          13           37               50               26              56                  5               11                 2
                           9950 Polycythemia vera                                                                                                                                                                                                                    
                           9961 Myelosclerosis with myeloid metaplasia                                                                                                                                                                           
                           9962 Essential thrombocythemia                                                                                                                                                                                                  
                           9963 Chronic neutrophilic leukemia                                                                                                                                                                                            
                           9964 Hypereosinophilia syndrome                                                                                                                                                                                               
Subgroup 3                                                                                             3,488           50           8            29               63               19              68                  6                5                  2
                           9960 Chronic myeloproliferative disease, NOS
Myelodysplastic syndrome (MDS) 7,982 54 3 21 76 16 66 7 9 2
9980 Refractory anemia
9982 Refractory anemia with ring sideroblasts
9983 Refractory anemia with excess blasts
9985 Refractory cytopenia with multilineage dysplasia
9986 Myelodysplastic syndrome 5q-deletion
9989 Myelodysplastic syndrome, NOS
Myelodysplastic/ myeloproliferative neoplasms (MDS/MPN) 1,672 58 2 22 76 24 47 18 11 1
9945 Chronic myelomonocytic leukemia
9876 Atypical CML (BCR/ABL1-negative) 
9946 Juvenile myelomonocytic leukemia
9975 Myelodysplastic/myeloproliferative neoplasm,  unclassifiable
Myeloid malignancy of unknown type 3,759 52 9 26 65 17 31 7 30 14
Leukemia, NOS 2,747 51 9 25 66 21 35 7 27 11
9800 Leukemia, NOS
9801 Acute leukemia, NOS
9805 Acute leukemia, ambiguous lineage
Myeloid leukemia, NOS 1,012 54 9 27 64 7 22 8 40 23
9860 Myeloid leukemia, NOS
Totals 50,328 52 14 31 55 20 46 10 18 6
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autopsy or only from the death certificate, and two had
over 30% of cases with poorly specified morphology.
Patients in these registries (Northern Ireland, Wales,
Cracow, Austria, Firenze-Prato and Naples) were exclud-
ed from the survival analyses (Table 1). The remaining
cancer registries had 50,328 cases: 38% AML, 36% MPN,
16% MDS and 3% MDS/MPN. However, among these
there were 2,747 (5.5% of total) cases of leukemia NOS
(Table 2) whose morphological descriptions were insuffi-
cient to identify them as myeloid malignancies: these
cases were also excluded from the analyses.
Table 3 shows the results of the survival analyses as 5-
year relative survival for patients followed up in 2000-
2002, by subgroup and age (except for subgroups for
which the mean number of cases was less than 50). 
Five-year relative survival for all myeloid malignancies
was 37% (95%CI: 36.1-37.8), but differences between
the major categories were large; 5-year relative survival
was poorest for AML (17%) and best for MPN (63%).
Survival also differed within categories, particularly for
AML, where it ranged from 67% for acute promyelocytic
leukemia, through 38% for acute pan-myelosis with
myelofibrosis, down to 4% for refractory anemia with
excess blasts in transformation; for all other subtypes sur-
vival was less than 25%. 
Survival was more homogeneous among MPN sub-
types, although the survival rates of patients with
myelosclerosis with myeloid metaplasia and CML were
both rather low (35% and 45%, respectively). 
For patients with MDS, survival ranged from 12% for
those with refractory anemia with excess blasts to 56%
for those with refractory anemia with ring sideroblasts.
Because of low numbers of MDS/MPN cases it was pos-
sible to estimate survival only for cases with chronic
myelomonocytic leukemia (19%). 
Survival decreased with age in all major disease cate-
gories, but particularly for AML and MDS/MPN after the
age of 50 years. 
Estimates of survival each year after diagnosis are pre-
sented in Figure 1A-C. Survival declined markedly during
the first year for AML patients but was relatively stable in
successive years. Survival after the first year was good for
patients with acute promyelocytic leukemia, and
remained stable thereafter. For AML with multilineage
dysplasia, survival declined persistently from years 2 to 5.
For both MPN and MDS, survival declined steadily over
the 5 years; the decline was particularly evident for
patients with refractory anemia with excess blasts.
Analysis according to European region (Figure 2)
showed that 5-year age-adjusted relative survival for
patients with AML was fairly homogeneous across
Europe, ranging from 11% in Eastern Europe to 16% in
Northern and Central Europe. More marked regional dif-
ferences were evident for patients with acute promyelo-
cytic leukemia, with high survival in Northern Europe
(60%) and the UK and Ireland (64%), and poorer survival
in Central and Southern Europe (55%). 
Regional differences in survival were also marked for
patients with MPN, ranging from 74% in Northern
Europe to 27% in Eastern Europe. Survival was better in
Northern Europe and worse in Eastern Europe for all
MPN subtypes except MPN NOS. For CML, the 5-year
survival rates were 46% in Northern Europe, 40% in the
UK and Ireland, 42% in Southern Europe, 44% in Central
Europe, and 17% in Eastern Europe. 
Discussion
After reporting previously on the incidence of myeloid
malignancies across Europe in 2000-2002,12 we now report
on relative survival for these diseases, analyzing data from
42 cancer registries in 17 European countries. In the previ-
ous study12 we also investigated the completeness of the
HAEMACARE database, comparing incidence data
obtained from the HAEMACARE database with those
published in Cancer Incidence in Five Continents (CI5)
which can be considered the gold standard for cancer reg-
istration. We found similar incidence rates to those in CI5,
indicating that HAEMACARE data are as complete as
those of CI5. 
In spite of unavoidable bias due to variation in registra-
tion quality and coding practices, over 90% of cases (more
than 50,000 patients) had adequate morphology specifica-
tion and were used to estimate survival. To our knowledge
this is the largest European dataset used to analyze sur-
vival of patients with myeloid malignancies, making it
possible to assess and compare survival across the conti-
nent not only for common but also for relatively rare enti-
ties.
Europeans diagnosed with a myeloid malignancy gener-
ally have poor 5-year relative survival.19 Nevertheless sur-
vival varied markedly with subtype, being around 15% in
patients with AML but above 60% in those with MPN. 
AML is a long-established entity so comparisons of sur-
vival over time are possible. In Europe, the 5-year relative
survival rate improved from 10% in patients diagnosed in
1985-1989 to 14% in those diagnosed in 1995-1999,19,20
with no further improvement up to 2000-2002.21 For US
patients diagnosed with AML over the period 1999-2005,
the 5-year relative survival was higher at 23%.22
Survival of patients with AML with cytogenetic abnor-
malities was fairly good mainly because its common sub-
type – acute promyelocytic leukemia – can be effectively
treated with all-trans retinoic acid.23,24 Patients with other
subtypes of AML with cytogenetic abnormalities also
have good prognoses.25,26 Our finding that patients with
AML with multilineage dysplasia had the worst relative
survival is in accord with clinical data.27,28
Variation in survival for AML as a whole was fairly con-
tained across Europe, although patients did somewhat
better in Northern and Central Europe than in Eastern
Europe and the UK and Ireland. Variation in the survival of
patients with acute promyelocytic leukemia was not sta-
tistically significant given the limited number of cases.
This entity is treated effectively by a cheap vitamin A
derivative (all-trans retinoic acid)24. Note, however, that
population-based studies do not normally have access to
information on treatment. The interpretation of inter-
country differences in AML survival is further complicated
by the high percentage of AML NOS cases. These cases
may include poor prognosis patients and elderly who
undergo less intensive diagnostic work-up than better
prognosis and younger patients. An additional reason for
the large proportion of AML, NOS is probably that our
study protocol required morphologies coded according to
ICD-O-3 codes. Cases diagnosed before the adoption of
ICD-O-3 (year 2000 by most registries) were coded
according to ICD-O-1 or ICD-O-2. These codes were con-
verted into ICD-O-3 using IARC and EUROCARE rules.
Cases not classifiable into exact ICD-O-3 entities were
classified as AML NOS. 
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The availability and quality of morphology data varied
between cancer registries and countries and, although the
analysis was restricted to cancer registries with less than
30% NOS cases, the numbers of cases with poorly defined
morphology were relatively high,  pointing to the need for
the registries to obtain better quality information.
Centralized review of slides would have decreased the
proportion of NOS cases and improved the quality of our
data, but the resources were not available for such a task.
Literature data on the survival of patients with MPN are
scarce, except for those with the CML subtype.6,29 We
found that for most of MPN subtypes survival in Europe
was good, particularly for patients with polycythemia
vera and essential thrombocythemia, as reported in popu-
lation-based and clinical studies.29-32
CML has been correctly archived by cancer registries
since the 1970s, in coincidence with identification of the
causal t(9;22)(q34;q11) chromosome transition. Survival
improved from 37% in Europe in 1990-1994,5 to 45% in
the present study (Table 3). The introduction of tyrosine
kinase inhibitors to treat CML early in the new millenni-
um may have been partly responsible for this improve-
ment. These drugs are now first-line treatments for
CML.33 No information on the use of tyrosine kinase
inhibitors was available for the present study and it is pos-
sible that the dissemination of these treatments will result
in a further improvement in CML survival in the years
beyond those of the present study. 
The survival of European patients with CML was simi-
lar to that of US SEER patients diagnosed in 1984-1993.34
Table 3. Period estimates of 5-year relative survival (RS %) with 95% confidence intervals (CI) for European patients with myeloid malignancies alive in
2000-2002. RS is only shown for malignancies with a mean number of cases (Mean N) >50.
HAEMACARE ICD-O-3 code and description All ages Age Age 50-69 Age 70+
grouping (15-99) 15-49
Mean N1 RS (%) 95% CI RS (%) 95% CI RS (%) 95% CI RS (%) 95% CI
Acute myeloid leukemia (AML)2 7,111 17.0 (16.1-18.0) 47.4 (44.6-50.1) 15.4 (13.9-17.0) 2.7 (2.1-3.4)
AML, other2 6,716 15.1 (14.2-16.1) 43.6 (40.7-46.5) 14.0 (12.5-15.5) 2.5 (1.9-3.2)
9840 Acute erythroid leukemia 131 8.6 (4.4-14.5) 34.4 (15.5-54.2) 3.9 (0.7-12.3) 2.4 (0.3-8.9)
9861 AML, NOS 5,580 13.9 (12.9-14.9) 42.6 (39.3-45.8) 12.6 (11.1-14.2) 1.9 (1.4-2.6)
9867 Acute myelomonocytic leukemia 416 23.6 (19.0-28.6) 52.6 (41.1-63.0) 24.9 (17.6-32.9) 2.6 (0.7-7.0)
9873 AML, without maturation 51 23.1 (12.3-35.8) - - - - - -
9874 AML, with maturation 101 17.9 (10.4-27.1) - - 24.1 (12.0-38.5) - -
9891 Acute monocytic leukemia 297 18.6 (13.7-24.2) 49.6 (35.5-62.3) 12.3 (6.3-20.3) 3.9 (0.9-10.8)
9931 Acute pan-myelosis  88 37.5 (26.1-48.8) - - 37.6 (21.7-53.5) 33.1 (16.7-50.4)
with myelofibrosis
AML, with recurrent cytogenetic abnormalities2 269 64.1 (57.5-69.9) 78.2 (70.2-84.3) 59.7 (48.3-69.4) 13.5 (4.5-27.6)
9866 Acute promyelocytic 258 66.8 (60.0-72.8) 79.2 (71.1-85.3) 64.4 (52.0-74.4) 12.1 (3.6-26.2)
leukemia  t(15; 17) (q22; q11-12)
AML with multilineage dysplasia2 124 4.0 (1.2-9.8) - - 6.0 (1.1-17.1) - -
9984 Refractory anemia with excess 108 4.4 (1.2-10.7) - - 6.8 (1.2-19.5) - -
blasts in transformation (obsolete)
Myeloproliferative neoplasms (MPN)2 6,614 63.4 (61.8-64.9) 79.0 (76.3-81.4) 67.1 (64.9-69.2) 52.1 (49.6-54.6)
Chronic myeloid leukemia (CML)2 2,426 44.9 (42.6-47.3) 66.6 (62.5-70.3) 48.6 (44.8-52.2) 22.5 (19.3-25.8)
9863 CML, NOS 2,399 44.6 (42.3-47.0) 66.4 (62.3-70.2) 48.3 (44.6-52.0) 22.3 (19.1-25.6)
Other myeloproliferative neoplasms
Subgroup 22 2,844 82.3 (80.0-84.3) 96.0 (92.9-97.7) 83.2 (80.2-85.8) 76.6 (72.5-80.2)
9950 Polycythemia vera 1,382 84.8 (81.5-87.5) 94.9 (89.7-97.5) 86.4 (82.3-89.6) 79.4 (73.1-84.4)
9961 Myelosclerosis with 249 34.6 (27.6-41.6) - - 33.9 (23.6-44.5) 29.8 (20.7-39.5)
myeloid metaplasia  
9962 Essential thrombocythemia 1,230 89.9 (86.2-92.7) 98.9 (92.0-99.9) 90.4 (85.5-93.7) 85.8 (78.7-90.7)
Subgroup 3 9960 Chronic myeloproliferative 1,311 55.3 (51.5-58.9) 89.2 (81.3-93.9) 62.8 (57.1-68.0) 42.5 (37.5-47.5)
disease, NOS
Myelodysplastic syndrome (MDS)2 3,077 30.8 (28.8-32.8) 51.8 (42.0-60.7) 36.5 (32.7-40.3) 27.2 (24.8-29.7)
9980 Refractory anemia 462 49.0 (42.7-55.0) - - 52.3 (42.2-61.4) 43.9 (35.7-51.8)
9982 Refractory anemia 251 56.1 (47.1-64.2) - - 68.9 (52.4-80.7) 51.1 (40.2-60.9)
with ring sideroblasts
9983 Refractory anemia 361 11.5 (7.5-16.5) - - 9.0 (4.0-16.6) 12.2 (7.0-19.0)
with excess blasts
9989 Myelodysplastic syndrome, NOS 2,019 27.1 (24.7-29.5) 47.3 (35.1-58.5) 35.0 (30.2-39.8) 23.2 (20.5-25.9)
Myelodysplastic/myeloproliferative 650 19.6 (16.1-23.4) 73.5 (42.5-89.5) 24.8 (17.7-32.4) 16.6 (12.8-20.9)
neoplasms (MDS/MPN)2
9945 Chronic myelomonocytic 
leukemia 646 19.3 (15.7-23.0) - - 24.0 (17.0-31.6) 16.7 (12.8-21.0)
All  myeloid malignancies3 17,346 37.0 (36.1-37.8) 61.7 (59.7-63.6) 39.4 (38.1-40.8) 26.2 (25.0-27.3)
1Mean number of cases contributing to period estimates of 5-year survival for 2000-2002; 2ICD-O-3 codes as reported in Table 2; 3Excluding leukemia, NOS (as defined in Table 2) since
insufficient information was available to be sure that the disease was of myeloid lineage. - Insufficient cases to estimate 5-year relative survival.
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However, in more recent SEER cohorts22 (1999-2005), the
5-year relative survival of patients with CML was 53%.
Thus, survival in Europe for CML lags well behind that in
the USA. Furthermore, European patients were character-
ized by marked survival variation for this highly treatable
malignancy, with poor outcomes in Eastern Europe.
Population-based studies on MDS and MDS/MPN from
specialized European6,35,36 and USA registries37 are generally
carried out on a small-scale, whereas the present analysis
was based on over 10,000 European cases. The
MDS/MPN category is dominated by chronic
myelomonocytic leukemia which is associated with a
worse survival than MDS (this being one of the reasons
why it was separated from MDS).37 A large USA study29
estimated the 3-year relative survival to be 21% for
myelomonocytic leukemia and 45% for MDS, consistent
with European findings (Table 3). As suggested previous-
ly12 it is likely that MDS and MDS/MPN were underre-
m. maynadié et al.
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Figure 1. (A) Period estimates of relative survival in
2000-2002 by years from diagnosis for patients with
acute myeloid leukemia (AML), AML other, acute promye-
locytic leukemia (APL), and AML with multilineage dys-
plasia. (B) Period estimates of relative survival in 2000-
2002 by years from diagnosis for patients with myelopro-
liferative neoplasms (MPN), chronic myeloid leukemia
(CML), chronic myeloproliferative neoplasms NOS (chron-
ic MPD, NOS), polycythemia vera (PV), myelosclerosis
with myeloid metaplasia (MSMM), and essential throm-
bocythemia (ET). (C) Period estimates of relative survival
in 2000-2002 by years from diagnosis for patients with
myelodysplastic syndrome (MDS), myelodysplastic syn-
drome NOS (MDS, NOS), refractory anemia, refractory
anemia with ring sideroblasts, and refractory anemia
with excess blasts.
Figure 2. Age-adjusted period esti-
mates in 2000-2002 of 5-year relative
survival for patients with acute
myeloid leukemia (AML), acute
promyelocytic leukemia (APL), myelo-
proliferative neoplasm (MPN) and
chronic myeloid leukemia (CML), by
European region.
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ported in the present study as they were considered non-
malignant and hence not registered by most European
cancer registries until the adoption of the ICD-O-3.
Treatment for MDS remained static until relatively recent-
ly when drugs such as lenalidomide, azacytidine and
decitabine were introduced with encouraging results.39-42
However any population-based effect on survival of
patients with MDS will not be evident for several years. 
We found that the survival decreased markedly with age
for all myeloid malignancies, with a steeper decrease than
reported for most other cancers.5 In general this decline is
attributed to less rigorous application of treatment proto-
cols in older patients, in part because they often have co-
morbidities. Few clinical trials are conducted specifically
on older patients.43
To conclude, this is the first paper to present large-scale
European survival data for patients with myeloid malig-
nancies using prognosis-based groupings of entities
defined by the ICD-O-3/WHO classifications. We docu-
mented poor survival for Europeans diagnosed with AML
and MDS/MPN compared to those with MDS and CML.
We also identified differences in AML subtypes, with
good survival for patients with acute promyelocytic
leukemia and poor survival for those with AML with mul-
tilineage dysplasia. Poor survival in some parts of Europe,
particularly for treatable diseases such as CML, is of con-
cern to hematologists and public health authorities.
Appendix: HAEMACARE Working Group
Austria: M. Hackl (National Cancer Registry of Austria); Czech
Republic: J. Holub (West Bohemia Cancer Registry); France: M.
Maynadié (Côte d'Or Haematological Malignancies Cancer
Registry); Germany: B. Holleczek (Saarland Cancer Registry);
Iceland: L. Tryggvadottir (National Cancer Registry of Iceland);
Ireland: H. Comber (National Cancer Registry of Ireland); Italy: F.
Bellù (Alto Adige Cancer Registry), A. Giacomin (Biella Cancer
Registry), S. Ferretti (Ferrara Cancer Registry), E. Crocetti (Firenze
Cancer Registry), D. Serraino (Friuli Cancer Registry), M. Vercelli
(Liguria Cancer Registry and IST/University of Genoa), M.
Federico (Modena Cancer Registry), M. Fusco (Napoli Cancer
Registry), M. Michiara (Parma Cancer Registry), R. Tumino
(Ragusa Cancer Registry), L. Mangone (Reggio Emilia Cancer
Registry), F. Falcini (Romagna Cancer Registry), A. Iannelli
(Salerno Cancer Registry), M. Budroni (Sassari Cancer Registry),
R. Zanetti (Torino Cancer Registry), S. Piffer (Trento Cancer
Registry), F. La Rosa (Umbria Cancer Registry), P. Zambon
(Venetian Cancer Registry), M. Sant (Project Leader), C. Allemani,
F. Berrino, S. Sowe, C. Tereanu (Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan), R. Capocaccia, R. De Angelis, A.
Simonetti (National Centre for Epidemiology, Surveillance and
Health Promotion, Istituto Superiore di Sanità, Rome); Malta: K.
England (National Cancer Registry of Malta); Norway: F.
Langmark (National Cancer Registry of Norway); Poland: J.
Rachtan (Cracow Cancer Registry), R. Mezyk (Kielce Cancer
Registry), M. Zwierko (Warsaw Cancer Registry); Slovakia: M.
Ondrusova (National Cancer Registry of the Slovak Republic);
Slovenia: M. Primic-Žakelj (National Cancer Registry of Slovenia);
Spain: R. Marcos-Gragera (Girona Cancer Registry); Sweden: S.
Khan (National Cancer Registry of Sweden); Switzerland: G.
Jundt (Basel Cancer Registry), M. Usel (Geneva Cancer Registry),
S. M. Ess (St Gall Cancer Registry), A. Bordoni (Ticino Cancer
Registry); The Netherlands:, R. Otter (Comprehensive Cancer
Centre The Netherlands, Utrecht), S. Siesling (Comprehensive
Cancer Centre The Netherlands, Utrecht), O. Visser
(Comprehensive Cancer Centre The Netherlands, Utrecht), J. W.
Coebergh (Eindhoven Cancer Registry); UK–England: D.
Greenberg (Eastern Cancer Registration and Information Centre),
N. Easey (Northern and Yorkshire Cancer Registry), M. Roche
(Oxford Cancer Intelligence Unit), G. Lawrence (West-Midlands
Cancer Intelligence Unit); UK–Northern Ireland: A. Gavin
(Northern Ireland Cancer Registry); UK–Scotland: D. H. Brewster
(Scottish Cancer Registry); UK–Wales: J. Steward (Welsh Cancer
Intelligence & Surveillance Unit). 
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